New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
07:43 EDTOPHTOphthotech initiates first expansion study of Fovista therapy
Ophthotech Corporation announced today the initiation of the first of several planned expansion trials, in addition to the ongoing Fovista combination therapy Phase 3 clinical program. These expansion trials will investigate the potential role of Fovista combination therapy in reducing sub-retinal fibrosis, addressing sub-optimal treatment response and reducing treatment burden in wet age-related macular degeneration patients receiving anti-vascular endothelial growth factor monotherapy. The first expansion trial is a Phase 2a open-label study investigating the potential role of anti-platelet derived growth factor therapy in combination with anti-VEGF therapy in reducing sub-retinal fibrosis in wet AMD patients. The company also announced that a subgroup analysis showing a reduction of sub-retinal fibrosis and neovascular growth in patients receiving Fovista and Lucentis in the company’s Phase 2b trial has been accepted as an oral presentation at this year’s Annual Meeting of the American Academy of Ophthalmology, one of the major medical meetings for retinal physicians.
News For OPHT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 24, 2015
08:11 EDTOPHTOphthotech price target raised to $69 from $61 at Leerink
Leerink raised its price target for Ophthotech shares to $69 following the company's Q4 results and reiterates an Outperform rating on the name.
February 23, 2015
16:12 EDTOPHTOphthotech reports Q4 EPS ($1.06), consensus (57c)
Subscribe for More Information
February 18, 2015
10:05 EDTOPHTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:45 EDTOPHTOphthotech initiated with a Buy at Chardan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use